海辰药业：10月22日召开董事会会议

Company Overview - Haichen Pharmaceutical (SZ 300584) announced on October 22 that its fifth board meeting was held via telecommunication to review the full report for the third quarter of 2025 [1] - The company's revenue composition for the period from January to December 2024 is entirely from the pharmaceutical manufacturing sector, accounting for 100.0% [1] - As of the report, Haichen Pharmaceutical has a market capitalization of 6.7 billion yuan [1]